Seres Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Oct 2025 | Sep 2025 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $736.0K | $358.0K | — | — | — | $351.0K | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $9.1M | $13.2M | — | — | — | $12.6M | — |
| SG&A Expense | — | $7.1M | $8.1M | — | — | — | $9.5M | — |
| Operating Income | — | $-21.3M | $-20.9M | — | — | — | $-22.5M | — |
| Operating Margin | — | -2,890.4% | -5,839.9% | — | — | — | -6,403.7% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — | — | — | $0 | — |
| Net Income | — | $4.6M | $-19.9M | — | — | — | $8.2M | — |
| Net Margin | — | 622.4% | -5,562.3% | — | — | — | 2,337.3% | — |
| EPS (Basic) | — | $0.47 | $-2.08 | — | — | — | $0.94 | — |
| EPS (Diluted) | — | $0.47 | $-2.08 | — | — | — | $0.94 | — |
| Shares Outstanding (Basic) | 9.9M | 9.7M | 9.6M | 9.6M | 9.6M | 9.0M | 8.8M | 8.8M |
| Shares Outstanding (Diluted) | 9.9M | 9.7M | 9.6M | 9.6M | 9.6M | 9.0M | 8.8M | 8.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |